T1	Participants 4 125	simvastatin improve erectile function and health-related quality of life in men aged ≥40 years with erectile dysfunction?
T2	Participants 141 195	Erectile Dysfunction and Statins Trial [ISRCTN66772971
T3	Participants 336 385	men aged ≥40 years with erectile dysfunction (ED)
T4	Participants 733 767	173 eligible men with untreated ED
T5	Participants 800 871	treatment with 40 mg of simvastatin or placebo once daily for 6 months.
T6	Participants 913 921	30 weeks
T7	Participants 923 961	The main outcome was erectile function
T8	Participants 1042 1163	male ED-specific quality of life (MED-QoL), quality-adjusted life years (QALYs) using the generic Euroqol measure (EQ-5D)
T9	Participants 1498 1566	10-year cardiovascular risk and low-density lipoprotein were reduced
T10	Participants 1710 1790	The frequency of sexual encounters is correlated with improved erectile function
T11	Participants 1857 1995	the probability of simvastatin being cost-effective for willingness-to-pay thresholds of £20,000 and £30,000 is 86% and 83%, respectively.
T12	Participants 2029 2158	ED provides an opportunity to modify future cardiovascular risk and to improve MED-QoL by treating them with 40 mg of simvastatin
T13	Participants 2308 2464	The findings could influence urological and primary care practice by including questions on ED during routine consultations and relevant clinical protocols.
T14	Participants 2465 2521	This provides an opportunity to impart lifestyle advice.
